Commit Biologics Raises $60 Million to Advance COM002 Toward Trials
Commit Biologics completed a $60 million seed round led by Ackermans & van Haaren to move T-cell-independent COM002 toward clinical testing and develop more complement engager candidates.
By Amara Osei
3 min read

What's News
- Commit Biologics completed a $60 million seed financing.
- Ackermans & van Haaren led the final close; AbbVie Ventures and M Ventures joined as new investors.
- Existing investors Bioquube Ventures, Korys and Novo Holdings also participated.
- COM002 is designed to eliminate targeted cells independently of T cells.
- Preclinical findings do not establish safety or effectiveness in people.
By Amara Osei
Commit Biologics has completed a $60 million seed financing to advance COM002, its lead bispecific complement engager, toward clinical development, the company said. Ackermans & van Haaren led the final close of the round, which supports further work on the company’s platform.
Commit Biologics said AbbVie Ventures and M Ventures joined the financing as new investors. Existing investors Bioquube Ventures, Korys and Novo Holdings also participated in the seed round.
How does Commit’s complement platform work?
Commit Biologics is developing bispecific complement engagers designed to direct the complement system against diseased cells, the company said. It describes complement as an important component of the immune response, while noting that the mechanism has remained relatively underused as a therapeutic route.
COM002 is the company’s lead candidate and is designed to eliminate targeted cells independently of T cells, according to Commit. Its proposed function therefore rests on directing complement rather than relying on T cells, the approach Commit selected for its first development candidate.
Thomas L. F. Montgomery Andresen is CEO of Commit Biologics. He said: “Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells.”
Andresen tied the financing to COM002’s clinical progression and the broader platform. He said: “With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy.”
Andresen said: “Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.” That was his assessment of the investor group backing the company’s first candidate.
What does the $60 million advance?
The financing will help Commit move COM002 toward clinical testing and develop additional candidates from its platform, the company said. Commit also plans to use the money to expand the scientific, manufacturing and operating foundation required to develop a new class of immunotherapies.
Commit’s stated use of proceeds extends beyond a single candidate. The financing links COM002’s path toward clinical testing, additional platform programs and the infrastructure needed to build the company’s immunotherapy pipeline, according to the company.
Charlotte Kremers, Principal at M Ventures, said: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development.” Her view framed the round around a programmable antibody platform.
She added: “Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.” That approach places the investment thesis at the platform level, rather than solely on COM002.
Lenny Van Steenhuyse is an Investment Manager at Ackermans & van Haaren. He said: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion.” The lead investor based its case on preclinical targeted-cell-depletion data.
He added: “Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE platform.” The statement made explicit the firm’s lead role in the financing.
What remains unproven?
Commit Biologics said preclinical findings do not establish safety or effectiveness in people. COM002 must complete required studies and regulatory reviews before the company can evaluate its performance in clinical trials.
The $60 million gives Commit resources for that sequence, but it does not answer whether the T-cell-independent approach will work in people. The next test is progression through required studies and regulatory reviews. Any clinical evaluation of COM002 will test the platform’s efficacy and safety claims after those requirements are met.
Source: pulse2.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,358 articles